Changes in serum levels of brain derived neurotrophic factor and nerve growth factor-beta in schizophrenic patients before and after treatment.

Ajami A, Hosseini SH, Taghipour M, Khalilian A. Changes in serum levels of brain derived neurotrophic factor and nerve growth factor-beta in schizophrenic patients before and after treatment. Scand J Immunol. 2014;80(1):36-42. DOI: 10.1111/sji.12158. PubMed PMID: 24498860.

Effects of olanzapine on plasma levels of catecholamine metabolites, cytokines, and brain-derived neurotrophic factor in schizophrenic patients.

Hori H, Yoshimura R, Yamada Y, Ikenouchi A, Mitoma M, Ida Y, et al. Effects of olanzapine on plasma levels of catecholamine metabolites, cytokines, and brain-derived neurotrophic factor in schizophrenic patients. Int Clin Psychopharmacol. 2007;22(1):21-7. DOI: 10.1097/YIC.0b013e3280103593. PubMed PMID: 17159456.

Reduced brain-derived neurotrophic factor serum concentrations in acute schizophrenic patients increase during antipsychotic treatment.

Lee AH, Lange C, Ricken R, Hellweg R, Lang UE. Reduced brain-derived neurotrophic factor serum concentrations in acute schizophrenic patients increase during antipsychotic treatment. J Clin Psychopharmacol. 2011;31(3):334-6. DOI: 10.1097/JCP.0b013e31821895c1. PubMed PMID: 21508862.

Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction.

D'Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G, et al. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry. 2005;57(6):594-608. DOI: 10.1016/j.biopsych.2004.12.006. PubMed PMID: 15780846.

Cannabidiol monotherapy for treatment-resistant schizophrenia.

Zuardi AW, Hallak JEC, Dursun SM, Morais SL, Sanches RF, Musty RE, et al. Cannabidiol monotherapy for treatment-resistant schizophrenia. J Psychopharmacol. 2006;20(5):683-6. DOI: 10.1177/0269881106060967. PubMed PMID: 16401651.

Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action.

Zuardi AW. Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Rev Bras Psiquiatr. 2008;30(3):271-80. PubMed PMID: 18833429.

Absence of N-Methyl-D-Aspartate Receptor IgG Autoantibodies in Schizophrenia: The Importance of Cross-Validation Studies.

de Witte LD, Hoffmann C, van Mierlo HC, Titulaer MJ, Kahn RS, Martinez-Martinez P. Absence of N-Methyl-D-Aspartate Receptor IgG Autoantibodies in Schizophrenia: The Importance of Cross-Validation Studies. Jama Psychiatry. 2015;72(7):731-3. DOI: 10.1001/jamapsychiatry.2015.0526. PubMed PMID: 25970159.

Disease-relevant autoantibodies in first episode schizophrenia.

Zandi MS, Irani SR, Lang B, Waters P, Jones PB, McKenna P, et al. Disease-relevant autoantibodies in first episode schizophrenia. J Neurol. 2011;258(4):686-8. DOI: 10.1007/s00415-010-5788-9. PubMed PMID: 20972895; PubMed Central PMCID: PMC3065649.

Increased prevalence of diverse N-methyl-D-aspartate glutamate receptor antibodies in patients with an initial diagnosis of schizophrenia: specific relevance of IgG NR1a antibodies for distinction from N-methyl-D-aspartate glutamate receptor encephalitis.

Steiner J, Walter M, Glanz W, Sarnyai Z, Bernstein H-G, Vielhaber S, et al. Increased prevalence of diverse N-methyl-D-aspartate glutamate receptor antibodies in patients with an initial diagnosis of schizophrenia: specific relevance of IgG NR1a antibodies for distinction from N-methyl-D-aspartate glutamate receptor encephalitis. Jama Psychiatry. 2013;70(3):271-8. DOI: 10.1001/2013.jamapsychiatry.86. PubMed PMID: 23344076.

Psychiatric manifestations of anti-NMDA receptor encephalitis: neurobiological underpinnings and differential diagnostic implications.

Maneta E, Garcia G. Psychiatric manifestations of anti-NMDA receptor encephalitis: neurobiological underpinnings and differential diagnostic implications. Psychosomatics. 2014;55(1):37-44. DOI: 10.1016/j.psym.2013.06.002. PubMed PMID: 23932531.